US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
pharma · Contraception · Chlamydia Trachomatis Infection · EVFM
Evofem Biosciences
Evofem Biosciences drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2015 Founded
39 Employees
Public company Type
EVFM · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2015
- Employees
- 39
- Programs
- 6
- Drugs
- 2
- Patents
- 8
Evofem Biosciences pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Evofem Biosciences drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor